Onconetix, Inc. Accrued Marketing Costs, Current
Onconetix, Inc. (ONCO) had Accrued Marketing Costs, Current of $93.79 thousand as of 2024-03-31, per its 10-Q filed 2024-05-20.
Financial Statements › Notes › Payables and Accruals › Accrued Liabilities, Current
us-gaap:AccruedMarketingCostsCurrent · last filed 2025-06-02
- 2024-03-31: Accrued Marketing Costs, Current $93.79K.
- 2023-12-31: Accrued Marketing Costs, Current $93.79K.
- 2023-09-30: Accrued Marketing Costs, Current $106.29K.
| Period end | Accrued Marketing Costs, Current |
|---|---|
| 2024-03-31 | $93.79K 10-Q · filed 2024-05-20 |
| 2023-12-31 | $93.79K 10-K · filed 2025-06-02 |
| 2023-09-30 | $106.29K 10-Q · filed 2023-11-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |